The Federal Trade Commission has filed a lawsuit to prevent Amgen’s acquisition of Horizon Therapeutics, citing concerns about potential competition limitations in the pharmaceutical industry.
According to the FTC, the agreement would strengthen Amgen’s dominance over two of Horizon’s popular drugs: Tepezza for thyroid eye disease, and Krystexxa for gout treatment.
The agency stated that Amgen could provide rebates for their current drugs in an effort to encourage insurers and pharmacy benefit managers to prioritize the two Horizon products through cross-market bundling.
The Federal Trade Commission asserted that Amgen, a company based in California, has a record of using its drug portfolio to obtain benefits over potential competitors.
Related: Amgen, Teva Get Can Appeal Sensipar Antitrust Ruling
The FTC received a suit regarding the acquisition and pending merger between Indivior and Opian, which Senator Elizabeth Warren had previously requested the regulator to scrutinize due to concerns about potential price increases.
“Today’s action – the FTC’s first challenge to a pharmaceutical merger in recent memory – sends a clear signal to the market: The FTC won’t hesitate to challenge mergers that enable pharmaceutical conglomerates to entrench their monopolies at the expense of consumers and fair competition,” said Holly Vedova, agency’s bureau of competition director, in a statement.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI